Nothing Special   »   [go: up one dir, main page]

DE4133366A1 - Aminoacid compsn. for prevention of hypoxic cell damage - contains glycine, serine, alanine, aspartic acid or glutamic acid or mixt. - Google Patents

Aminoacid compsn. for prevention of hypoxic cell damage - contains glycine, serine, alanine, aspartic acid or glutamic acid or mixt.

Info

Publication number
DE4133366A1
DE4133366A1 DE19914133366 DE4133366A DE4133366A1 DE 4133366 A1 DE4133366 A1 DE 4133366A1 DE 19914133366 DE19914133366 DE 19914133366 DE 4133366 A DE4133366 A DE 4133366A DE 4133366 A1 DE4133366 A1 DE 4133366A1
Authority
DE
Germany
Prior art keywords
serine
mmol
glycine
compsn
alanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19914133366
Other languages
German (de)
Inventor
Bernhard Dr Sixt
A Fausto E Dr Machicao
Stefan Dr Dr Bertsch
Groot Herbert Dr Dr De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nycomed Arzneimittel GmbH
Original Assignee
Nycomed Arzneimittel GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Arzneimittel GmbH filed Critical Nycomed Arzneimittel GmbH
Priority to DE19914133366 priority Critical patent/DE4133366A1/en
Publication of DE4133366A1 publication Critical patent/DE4133366A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Compsn. (A) contains 0.1-30 mmol/l of glycine, serine, alanine, aspartic acid or glutamic acid or a mixt. of these aminoacids. (A) pref. contains 0.2-10 mmol/l of the aminoacid(s). An esp. pref. compsn. (A) contains glycine and/or serine in a concn. of 0.1-10 mmol/l. USE - (A) is used to reduce or prevent hypoxic damage in human and animal tissue, e.g. liver kidney, intestine and pancreas. It is esp. effective during operations, including transplants, where it is perfused into the organs as a soln. In an example, the effect of glycine at 10 mmol/l on hypoxic cell damage to rat hepatocytes was tested using lactate dehydrogenase (LDH) liberation to measure damage. LDH liberation was 5%, 7% and 10% after 2, 4 and 6 hrs., compared with 50%, 65% and 75% for control over the same period.

Description

Die Erfindung betrifft eine Zusammensetzung, die durch Sauer­ stoffunterversorgung in tierischen oder menschlichen Geweben entstehende Schäden verhindert.The invention relates to a composition by Sauer Undersupply of substances in animal or human tissues prevents damage occurring.

Sauerstoffunterversorgung, Hypoxie, in Geweben entsteht bei­ spielsweise bei peripheren oder cerebralen Durchblutungsstö­ rungen, Schlaganfall, Gefäßverschluß oder auch bei Lagerung von Transplantationsorganen.Undersupply of oxygen, hypoxia, arises in tissues for example with peripheral or cerebral circulatory disorders stakes, stroke, vascular occlusion or even during storage of transplant organs.

Aus T.S. Rao et al., Neuropharmacology 29 (1990), Seiten 1199 bis 1204 ist bekannt, Opipramol, ein trizyklisches Antidepres­ sivum zur Verminderung oder Vermeidung von Schäden durch Sauerstoffunterversorgung im Gehirn einzusetzen.From T.S. Rao et al., Neuropharmacology 29 (1990), pages 1199 to 1204 is known opipramol, a tricyclic antidepres sivum to reduce or prevent damage from To use oxygen deficiency in the brain.

Ferner ist aus de Groot et al., Res. Commun. Chem. Pathol. Pharmacol. 68, Seiten 125 bis 128, bekannt, daß ein protein­ freier Extrakt aus Kälberblut eine deutliche Verminderung ei­ ner hypoxischen Leberschädigung bewirkt.Furthermore, de Groot et al., Res. Commun. Chem. Pathol. Pharmacol. 68, pages 125 to 128, known that a protein free extract from calf blood a significant reduction causes hypoxic liver damage.

Es konnte nun unerwarteterweise gefunden werden, daß bestimmte Aminosäuren oder deren Mischungen die Schäden der Sauerstoffunterversorgung in Geweben mindern bzw. weitgehend verhindern.It was now unexpectedly found that certain Amino acids or their mixtures damage the Reduce or largely undersupply of oxygen in tissues prevent.

Gegenstand der Erfindung ist daher eine Zusammensetzung zur Verhinderung von Schäden in tierischen oder menschlichen Gewe­ ben durch Sauerstoffunterversorgung, gekennzeichnet durch einen Gehalt an 0,1-30 mmol/l an Aminosäuremischung beste­ hend aus den Aminosäuren Glycin und/oder Serin und/oder Alanin und/oder Asparaginsäure und/oder Glutaminsäure. The invention therefore relates to a composition for Prevention of damage to animal or human tissues ben by oxygen deficiency, characterized by best content of 0.1-30 mmol / l of amino acid mixture starting from the amino acids glycine and / or serine and / or alanine and / or aspartic acid and / or glutamic acid.  

Die genannten Aminosäuren zeigen allein oder in Mischung eine ausgezeichnete protektive Wirkung gegen Schäden, die durch Sauerstoffunterversorgung in tierischen oder menschlichen Ge­ weben auftreten.The amino acids mentioned show one alone or in a mixture excellent protective effect against damage caused by Undersupply of oxygen in animal or human ge weaving occur.

Die Aminosäuren werden allein oder in Kombination in einer Konzentration von 0,1 bis 30 mmol/l, vorzugsweise 0,2 bis 10 mmol/l eingesetzt, wobei die Gesamtkonzentration 30 mmol/l nicht übersteigen soll.The amino acids are used alone or in combination in one Concentration of 0.1 to 30 mmol / l, preferably 0.2 to 10 mmol / l, the total concentration being 30 mmol / l should not exceed.

Vorzugsweise enthält die erfindungsgemäße Zusammensetzung die Aminosäuren Glycin und/oder Serin allein oder in Kombination mit einer oder mehreren Aminosäuren aus der Gruppe Alanin, As­ paraginsäure und Glutaminsaure.The composition according to the invention preferably contains the Amino acids glycine and / or serine alone or in combination with one or more amino acids from the group alanine, As paraginic acid and glutamic acid.

Die erfindungsgemäße Zusammensetzung kann unter anderem zur Verhinderung von hypoxischen Schädigungen von Leber, Niere und anderen parenchymatösen Organen, wie z. B. Darm und Pan­ kreas, eingesetzt werden.The composition according to the invention can be used, inter alia, for Prevention of hypoxic damage to the liver, kidney and other parenchymatous organs, such as. B. gut and pan kreas, can be used.

Insbesonders eignen sich die erfindungsgemäßen Zusammensetzun­ gen zur optimalen Versorgung solcher Organe, die während Transplantationen oder anderen Operationen vorübergehend nicht ausreichend mit Sauerstoff versorgt werden können.The compositions according to the invention are particularly suitable conditions for optimal care of such organs that during Transplants or other surgeries are temporarily unavailable can be adequately supplied with oxygen.

Beispielsweise können die vorübergehend stillgelegten Organe mit den Aminosäurelösungen vorperfundiert werden, sodaß in der Ischämie die Organzellen konstant mit den Aminosäuren versorgt werden.For example, the temporarily decommissioned organs be pre-perfused with the amino acid solutions, so that in the Ischemia constantly supplies the organ cells with the amino acids will.

Beispiel 1Example 1

Untersuchung der Schutzwirkung der Aminosäuren auf die hypo­ xische Zellschädigung an Rattenhepatozyten in Primärkultur.Investigation of the protective effect of amino acids on the hypo Xical cell damage to rat hepatocytes in primary culture.

Die zu untersuchenden Leberzellen wurden aus gefütterten, männlichen Wistarratten durch Kollagenase-Perfusion, wie in Biol. Chem. Hoppe-Seyler (1991) 372, Seiten 34 bis 41 be­ schrieben, isoliert.The liver cells to be examined were derived from male Wistar rats by collagenase perfusion, as in Biol. Chem. Hoppe-Seyler (1991) 372, pages 34 to 41 wrote, isolated.

Pro Kulturflasche wurden 3·106 Zellen aufgegeben und in Leibo­ witz L15-Medium kultiviert. Zur Durchführung der Untersuchung wurden 24 Stunden alte Kulturen verwendet. Als Versuchsmedium diente Krebs-Henseleit-Puffer, pH 7,4, der zusätzlich 20 mmol/l Hepes und 83 µmol/l Trypanblau enthielt. Die Temperatur der Versuchsanordnung betrug 37°C. Die in 0,5 ml Inkubationspuffer gelösten Aminosäuren wurden direkt vor Beginn der hypoxischen Inkubationen zugegeben. Das Gesamtvolumen an Inkubationspuffer betrug 5,5 ml. Den Kontrollen wurden ebenfalls 0,5 ml Inkubationspuffer zugesetzt. Die Zellschädigung wurde durch Aufnahme von Trypanblau sowie durch die Freisetzung der Lactat-Dehydro­ genase bestimmt.3 × 10 6 cells were added to each culture bottle and cultured in Leibo witz L15 medium. Cultures 24 hours old were used to conduct the study. Krebs-Henseleit buffer, pH 7.4, which also contained 20 mmol / l Hepes and 83 µmol / l trypan blue, was used as the test medium. The temperature of the experimental set-up was 37 ° C. The amino acids dissolved in 0.5 ml incubation buffer were added immediately before the start of the hypoxic incubations. The total volume of incubation buffer was 5.5 ml. 0.5 ml incubation buffer was also added to the controls. The cell damage was determined by ingestion of trypan blue and by the release of lactate dehydrogenase.

Die Versuche zeigten, daß die Rattenhepatozyten in Primärkul­ tur unter hypoxischen Bedingungen bereits nach 2 Stunden eine erhebliche Schädigung aufwiesen. Nach 6 h Inkubation hatten bereits 75% der Zellen ihre Vitalität verloren. Bei Zugabe der Aminosäuren konnte jedoch eine deutliche Verminderung der Schädigungen festgestellt. Die Schutzwirkungen der Aminosäuren Glycin, Serin, Alanin, Aparigin- und Glutaminsäure sind in den folgenden Tabellen dargestellt.The experiments showed that the rat hepatocytes in primary culture structure under hypoxic conditions after 2 hours showed significant damage. After 6 h of incubation 75% of the cells already lost their vitality. When adding of the amino acids, however, was able to reduce the Damages found. The protective effects of amino acids Glycine, serine, alanine, apariginic and glutamic acid are in the shown in the following tables.

Die Zellschädigung wurde dabei durch die Freisetzung der Lac­ tat-Dehydrogenase (LDH) bestimmt.The cell damage was caused by the release of the lac tat dehydrogenase (LDH) determined.

Die Kontrollwerte geben die LDH-Freisetzung ohne Aminosäure­ zugabe an. The control values give the LDH release without amino acid addition to.  

Tabelle 1 Table 1

Tabelle 2 Table 2

Tabelle 3 Table 3

Tabelle 4 Table 4

Tabelle 5 Table 5

Claims (4)

1. Zusammensetzung zur Verhinderung von Schäden in tierischen oder menschlichen Geweben durch Sauerstoffunterversorgung, gekennzeichnet durch einen Gehalt an 0,1 bis 30 mmol/l Aminosäuremischung bestehend aus den Aminosäuren Glycin und/oder Serin und/oder Alanin und/oder Asparaginsäure und/oder Glutaminsäure.1. Composition for preventing damage in animal or human tissues by oxygen deficiency, characterized by a content of 0.1 to 30 mmol / l amino acid mixture consisting of the amino acids glycine and / or serine and / or alanine and / or aspartic acid and / or glutamic acid . 2. Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, daß sie die Aminosäuren Glycin und/oder Serin enthält.2. Composition according to claim 1, characterized in that it contains the amino acids glycine and / or serine. 3. Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, daß die Summe der Konzentration der Aminosäuren 0,2 bis 10 mmol/l beträgt.3. Composition according to claim 1, characterized in that the sum of the concentration of amino acids 0.2 to 10 mmol / l. 4. Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, daß sie 0,1 bis 10 mmol/l Glycin und/oder Serin enthält.4. Composition according to claim 1, characterized in that it contains 0.1 to 10 mmol / l glycine and / or serine.
DE19914133366 1991-10-09 1991-10-09 Aminoacid compsn. for prevention of hypoxic cell damage - contains glycine, serine, alanine, aspartic acid or glutamic acid or mixt. Withdrawn DE4133366A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19914133366 DE4133366A1 (en) 1991-10-09 1991-10-09 Aminoacid compsn. for prevention of hypoxic cell damage - contains glycine, serine, alanine, aspartic acid or glutamic acid or mixt.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19914133366 DE4133366A1 (en) 1991-10-09 1991-10-09 Aminoacid compsn. for prevention of hypoxic cell damage - contains glycine, serine, alanine, aspartic acid or glutamic acid or mixt.

Publications (1)

Publication Number Publication Date
DE4133366A1 true DE4133366A1 (en) 1993-04-15

Family

ID=6442293

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19914133366 Withdrawn DE4133366A1 (en) 1991-10-09 1991-10-09 Aminoacid compsn. for prevention of hypoxic cell damage - contains glycine, serine, alanine, aspartic acid or glutamic acid or mixt.

Country Status (1)

Country Link
DE (1) DE4133366A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2715028A1 (en) * 1994-01-17 1995-07-21 Charrueau Christine Soln for preserving organs, tissues etc contg amino acids
EP0713363A1 (en) * 1993-08-12 1996-05-29 The University Of North Carolina At Chapel Hill Rinse solution for organs and tissues
EP0758234A1 (en) * 1994-04-29 1997-02-19 Wake Forest University Method and composition for treating renal disease and failure
WO1997011694A1 (en) * 1995-09-25 1997-04-03 Desitin Arzneimittel Gmbh Creatine for the protection of neural tissue
US6048543A (en) * 1995-06-14 2000-04-11 Novartis Nutrition Ag Amino acid compositions and use thereof in clinical nutrition
WO2006030980A1 (en) 2004-09-17 2006-03-23 Ajinomoto Co., Inc. Agent and food for preventing/improving functional digestive disorder
DE102017131059A1 (en) 2017-12-22 2019-06-27 Christiane Kappert Physiologically acceptable solution containing pyruvate and glycine, a composition containing pyruvate and glycine, and a process for the preparation thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450841A (en) * 1982-03-03 1984-05-29 Thomas Jefferson University Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
EP0144489A2 (en) * 1983-04-28 1985-06-19 Rolf Dr. Eurich Use of an antihypoxidoticum with cerebral and peripheral effect
DE3820840C1 (en) * 1988-06-21 1989-11-09 Friedhelm Dr. 6200 Wiesbaden De Beyersdorf Aqueous reperfusion solution for reducing the reperfusion damage after acute peripheral vascular occlusion

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450841A (en) * 1982-03-03 1984-05-29 Thomas Jefferson University Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
EP0144489A2 (en) * 1983-04-28 1985-06-19 Rolf Dr. Eurich Use of an antihypoxidoticum with cerebral and peripheral effect
DE3820840C1 (en) * 1988-06-21 1989-11-09 Friedhelm Dr. 6200 Wiesbaden De Beyersdorf Aqueous reperfusion solution for reducing the reperfusion damage after acute peripheral vascular occlusion

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts , Vol.115, 1981, Ref. 287257r *
Derwent Abstracts 89-146406/34 zu JP 1180-823-A *
et.al.: In: Am.J.Cardiol. 68(4), 1991,S.291-5, Medline 91314451 *
KOKAS, P.: In: Acta Hepato- gastroenterol. 26 (4), 1979, S.284-9, Medline 80038639 *
KUPESULIK, P. *
THOMASSEN, A. *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0713363A1 (en) * 1993-08-12 1996-05-29 The University Of North Carolina At Chapel Hill Rinse solution for organs and tissues
EP0713363A4 (en) * 1993-08-12 1998-06-10 Univ North Carolina Rinse solution for organs and tissues
US6080730A (en) * 1993-08-12 2000-06-27 The University Of North Carolina At Chapel Hill Rinse solution for organs and tissues
FR2715028A1 (en) * 1994-01-17 1995-07-21 Charrueau Christine Soln for preserving organs, tissues etc contg amino acids
EP0758234A1 (en) * 1994-04-29 1997-02-19 Wake Forest University Method and composition for treating renal disease and failure
EP0758234A4 (en) * 1994-04-29 1997-06-25 Univ Wake Forest Method and composition for treating renal disease and failure
US6048543A (en) * 1995-06-14 2000-04-11 Novartis Nutrition Ag Amino acid compositions and use thereof in clinical nutrition
WO1997011694A1 (en) * 1995-09-25 1997-04-03 Desitin Arzneimittel Gmbh Creatine for the protection of neural tissue
WO2006030980A1 (en) 2004-09-17 2006-03-23 Ajinomoto Co., Inc. Agent and food for preventing/improving functional digestive disorder
EP2103306A2 (en) 2004-09-17 2009-09-23 Ajinomoto Co., Inc. Use of a 5'-nucleotide for preventing/improving functional digestive disorder
EP2305241A1 (en) 2004-09-17 2011-04-06 Ajinomoto Co., Inc. Use of a 5'-nucleotide for preventing/improving functional digestive disorder
DE102017131059A1 (en) 2017-12-22 2019-06-27 Christiane Kappert Physiologically acceptable solution containing pyruvate and glycine, a composition containing pyruvate and glycine, and a process for the preparation thereof

Similar Documents

Publication Publication Date Title
DE69129294T2 (en) COMPOSITION TO IMPROVE LIFE CONSERVATION OF BIOLOGICAL MATERIALS
Marks et al. Protein breakdown in the brain. Subcellular distribution and properties of neutral and acid proteinases
DE60012612T2 (en) Diluent for the cryopreservation of bovine semen
EP0513862A2 (en) Use of topical applicable preparation for treating skin aging
CH616942A5 (en) Method for suppressing the immunogenic action of a biocatalyst.
DE69717293T2 (en) PHARMACEUTICAL FORMULATIONS FROM CORTICOTROPIN RELEASING FACTOR WITH IMPROVED STABILITY IN LIQUID FORM
DE3715662A1 (en) NEW PHARMACEUTICAL APPLICATION
DE4133366A1 (en) Aminoacid compsn. for prevention of hypoxic cell damage - contains glycine, serine, alanine, aspartic acid or glutamic acid or mixt.
EP0552516B1 (en) Aqueous synthetic organ-extracts
DE69303343T2 (en) Blood preservation composition and method
EP1485120B1 (en) Use of one or more natural or modified oxygen carriers, devoid of plasma and cellular membrane constituents, for externally treating open, in particular chronic wounds
DE3686702T2 (en) BIOLOGICALLY ACTIVE TOPIC COLLAGEN CARRIER MATRIX: COSMETIC AND PHARMACEUTICAL USE AND METHOD FOR THE PRODUCTION THEREOF.
EP0046979A1 (en) Insulin analogues
DE2928880C2 (en) Standard bilirubin preparation with improved stability
DE2637600A1 (en) DOPAMINE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS
DE2540971A1 (en) HAIR GROWTH PRODUCTS
DE69535263T2 (en) ANGIOTENSIN II FOR IMPROVING FERTILIZATION
DE1467981A1 (en) Process for obtaining extracts for opotherapy and, more generally, of extracts derived from living tissues
Masini et al. Histamine and lactate dehydrogenase (LDH) release in ischemic myocardium of the guinea-pig
DE69607417T2 (en) Use of medicines containing batroxobin for the treatment and prophylaxis of ischemic reperfusion damage
DE1518282C3 (en) Phe to the power of 2 -Om to the power of 8 -oxytocin and process for its preparation
Shimizu et al. Richner-Hanhart's syndrome: Electron microscopic study of the skin lesion
Bachelard Glucose-phosphorylating enzyme with high Km in human brain
CA2078712A1 (en) Composition comprising amino acids for the prevention of hypoxic damage and a process for its preparation
DE102007035642A1 (en) Substances for protecting cells and tissues against damage due to unfavorable conditions

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8139 Disposal/non-payment of the annual fee